ScinoPharm Taiwan, Ltd. (TPE:1789)

Market Cap	16.09B -8.5%
Revenue (ttm)	3.16B -7.1%
Net Income	136.95M -59.6%
EPS	0.17 -60.4%
Shares Out	790.74M
PE Ratio	119.71
Forward PE	n/a
Dividend	0.29 (1.43%)
Ex-Dividend Date	Jul 3, 2025

Volume	849,227
Average Volume	1,157,313
Open	20.55
Previous Close	20.55
Day's Range	20.20 - 20.75
52-Week Range	16.25 - 29.10
Beta	0.54
RSI	41.01
Earnings Date	May 4, 2026

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd., a pharmaceutical company, provides active pharmaceutical ingredient (API) development and manufacturing and injectable solutions in Taiwan, rest of Asia, Europe, and the Americas. It offers small molecules, peptide drugs, and steroids; drug products for anticancer, thromboembolic disorders, and osteoporosis; and contract analytical testing, sterile injectables contract manufacturing, and small molecules and peptide contract development and manufacturing organization services. The company was incorporated in 1997 and is ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 540
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1789

Financial Performance

In 2025, ScinoPharm Taiwan's revenue was 3.16 billion, a decrease of -7.13% compared to the previous year's 3.41 billion. Earnings were 136.95 million, a decrease of -59.64%.